Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2005-11-16 15:48:42 UTC |
---|
Update Date | 2022-09-22 17:43:46 UTC |
---|
HMDB ID | HMDB0001442 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Prostaglandin E1 |
---|
Description | Prostaglandin E1 (PGE1) is a potent endogenous vasodilator agent that increases peripheral blood flow. It inhibits platelet aggregation and has many other biological effects such as bronchodilation, mediation of inflammation, and various protective functions. The protective action of PGE1 has been shown on both experimental animal models of liver injury and patients with fulminant viral hepatitis. PGE1-treated cirrhotic rats had less hepatosplenomegaly, lower serum alanine aminotransferase levels and portal pressures, and higher arterial pressure than placebo-treated cirrhotic rats. There are several mechanisms of PGE1 hepatic cytoprotection: inhibiting T-cell mediated cytotoxicity, enhancing DNA synthesis of the injured liver after partial hepatectomy by stimulating cyclic AMP production, increasing ATP level in hepatic tissue to accelerate the recovery of mitochondrial respiratory function after reperfusion, and stabilizing membrane microviscosity. PGE1 is a prostanoid. The term prostanoid collectively describes prostaglandins, prostacyclins, and thromboxanes. Prostanoids are a subclass of the lipid mediator group known as eicosanoids. They are derived from C-20 polyunsaturated fatty acids, mainly dihomo-γ-linolenic (20:3n-6), arachidonic (20:4n-6), and eicosapentaenoic (20:5n-3) acids, through the action of cyclooxygenases-1 and -2 (COX-1 and COX-2) (PMID: 11819590 , 16986207 ). Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent and are able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis through receptor-mediated G-protein linked signalling pathways. |
---|
Structure | CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1 |
---|
Synonyms | Value | Source |
---|
(11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-Oic acid | ChEBI | (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate | ChEBI | 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid | ChEBI | Alprostadil | ChEBI | Alprostadilum | ChEBI | Befar | ChEBI | Caverject | ChEBI | Edex | ChEBI | Muse | ChEBI | PGE-1 | ChEBI | PGE1 | ChEBI | Prostin VR | ChEBI | Prostin VR pediatric | Kegg | (11a,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-Oate | Generator | (11a,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-Oic acid | Generator | (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-Oate | Generator | (11Α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-Oate | Generator | (11Α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-Oic acid | Generator | (13E)-(15S)-11a,15-Dihydroxy-9-oxoprost-13-enoate | Generator | (13E)-(15S)-11a,15-Dihydroxy-9-oxoprost-13-enoic acid | Generator | (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoic acid | Generator | (13E)-(15S)-11Α,15-dihydroxy-9-oxoprost-13-enoate | Generator | (13E)-(15S)-11Α,15-dihydroxy-9-oxoprost-13-enoic acid | Generator | 11a,15a-Dihydroxy-9-oxo-13-trans-prostenoate | Generator | 11a,15a-Dihydroxy-9-oxo-13-trans-prostenoic acid | Generator | 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoate | Generator | 11Α,15α-dihydroxy-9-oxo-13-trans-prostenoate | Generator | 11Α,15α-dihydroxy-9-oxo-13-trans-prostenoic acid | Generator | Abbott brand OF alprostadil | MeSH, HMDB | Minprog | MeSH, HMDB | Paladin brand OF alprostadil | MeSH, HMDB | Prostaglandin e1alpha | MeSH, HMDB | Schwarz pharma brand OF alprostadil | MeSH, HMDB | Astra brand OF alprostadil | MeSH, HMDB | Hoyer brand OF alprostadil | MeSH, HMDB | Sugiran | MeSH, HMDB | Allphar brand OF alprostadil | MeSH, HMDB | AstraZeneca brand OF alprostadil | MeSH, HMDB | lipo PGE1 | MeSH, HMDB | Viridal | MeSH, HMDB | lipo-PGE1 | MeSH, HMDB | Vasaprostan | MeSH, HMDB | Janssen brand OF alprostadil | MeSH, HMDB | PGE1alpha | MeSH, HMDB | Pharmacia brand 1 OF alprostadil | MeSH, HMDB | Prostavasin | MeSH, HMDB | Prostine VR | MeSH, HMDB | Pharmacia brand 2 OF alprostadil | MeSH, HMDB | Prostaglandin e1 | MeSH, KEGG | Schwarz brand OF alprostadil | MeSH, HMDB | Vivus brand OF alprostadil | MeSH, HMDB | Prink | KEGG, HMDB | Vitaros | KEGG, HMDB | Caverject impulse | ChEMBL, HMDB | U-10136prostin | ChEMBL, HMDB | U-10136alprostadil | ChEMBL, HMDB | (+)-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate | HMDB | (+)-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid | HMDB | (-)-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate | HMDB | (-)-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid | HMDB | (-)-Prostaglandin e1 | HMDB | (13E)-(15S)-11,15-Dihydroxy-9-oxoprost-13-enoate | HMDB | (13E)-(15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid | HMDB | (13E)-(15S)-11-alpha,15-Dihydroxy-9-oxoprost-13-enoate | HMDB | (13E)-(15S)-11-alpha,15-Dihydroxy-9-oxoprost-13-enoic acid | HMDB | 11,15-Dihydroxy-9-oxoprost-13-en-1-Oate | HMDB | 11,15-Dihydroxy-9-oxoprost-13-en-1-Oic acid | HMDB | 11,15-Dihydroxy-9-oxoprost-13-en-1-Oic acid (acd/name 4.0) | HMDB | 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate | HMDB | 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid | HMDB | Alprostadil prostoglandin e1 | HMDB | Alprostadil(usan) | HMDB | L-Prostaglandin e1 | HMDB |
|
---|
Chemical Formula | C20H34O5 |
---|
Average Molecular Weight | 354.487 |
---|
Monoisotopic Molecular Weight | 354.240624195 |
---|
IUPAC Name | 7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoic acid |
---|
Traditional Name | alprostadil |
---|
CAS Registry Number | 745-65-3 |
---|
SMILES | CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O |
---|
InChI Identifier | InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1 |
---|
InChI Key | GMVPRGQOIOIIMI-DWKJAMRDSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Fatty Acyls |
---|
Sub Class | Eicosanoids |
---|
Direct Parent | Prostaglandins and related compounds |
---|
Alternative Parents | |
---|
Substituents | - Prostaglandin skeleton
- Long-chain fatty acid
- Fatty alcohol
- Hydroxy fatty acid
- Cyclopentanol
- Cyclic alcohol
- Cyclic ketone
- Ketone
- Secondary alcohol
- Carboxylic acid
- Carboxylic acid derivative
- Monocarboxylic acid or derivatives
- Alcohol
- Hydrocarbon derivative
- Organic oxide
- Organic oxygen compound
- Carbonyl group
- Organooxygen compound
- Aliphatic homomonocyclic compound
|
---|
Molecular Framework | Aliphatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 115 - 116 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | 3.20 | AVDEEF,A ET AL. (1995) |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Prostaglandin E1,1TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O)O[Si](C)(C)C | 2820.8 | Semi standard non polar | 33892256 | Prostaglandin E1,1TMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C)CC(=O)[C@@H]1CCCCCCC(=O)O | 2745.3 | Semi standard non polar | 33892256 | Prostaglandin E1,1TMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C | 2785.3 | Semi standard non polar | 33892256 | Prostaglandin E1,1TMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@@H]1C(CCCCCCC(=O)O)=C(O[Si](C)(C)C)C[C@H]1O | 2835.5 | Semi standard non polar | 33892256 | Prostaglandin E1,1TMS,isomer #5 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C)[C@@H]1CCCCCCC(=O)O | 2729.3 | Semi standard non polar | 33892256 | Prostaglandin E1,2TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)CC(=O)[C@@H]1CCCCCCC(=O)O)O[Si](C)(C)C | 2748.5 | Semi standard non polar | 33892256 | Prostaglandin E1,2TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2811.4 | Semi standard non polar | 33892256 | Prostaglandin E1,2TMS,isomer #3 | CCCCC[C@@H](/C=C/[C@@H]1C(CCCCCCC(=O)O)=C(O[Si](C)(C)C)C[C@H]1O)O[Si](C)(C)C | 2870.3 | Semi standard non polar | 33892256 | Prostaglandin E1,2TMS,isomer #4 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C)[C@@H]1CCCCCCC(=O)O)O[Si](C)(C)C | 2754.3 | Semi standard non polar | 33892256 | Prostaglandin E1,2TMS,isomer #5 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C)CC(=O)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C | 2732.4 | Semi standard non polar | 33892256 | Prostaglandin E1,2TMS,isomer #6 | CCCCC[C@H](O)/C=C/[C@@H]1C(CCCCCCC(=O)O)=C(O[Si](C)(C)C)C[C@H]1O[Si](C)(C)C | 2824.5 | Semi standard non polar | 33892256 | Prostaglandin E1,2TMS,isomer #7 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C)C=C(O[Si](C)(C)C)[C@@H]1CCCCCCC(=O)O | 2769.5 | Semi standard non polar | 33892256 | Prostaglandin E1,2TMS,isomer #8 | CCCCC[C@H](O)/C=C/[C@@H]1C(CCCCCCC(=O)O[Si](C)(C)C)=C(O[Si](C)(C)C)C[C@H]1O | 2824.3 | Semi standard non polar | 33892256 | Prostaglandin E1,2TMS,isomer #9 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C | 2746.1 | Semi standard non polar | 33892256 | Prostaglandin E1,3TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)CC(=O)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2737.7 | Semi standard non polar | 33892256 | Prostaglandin E1,3TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@@H]1C(CCCCCCC(=O)O)=C(O[Si](C)(C)C)C[C@H]1O[Si](C)(C)C)O[Si](C)(C)C | 2808.2 | Semi standard non polar | 33892256 | Prostaglandin E1,3TMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C=C(O[Si](C)(C)C)[C@@H]1CCCCCCC(=O)O)O[Si](C)(C)C | 2790.2 | Semi standard non polar | 33892256 | Prostaglandin E1,3TMS,isomer #4 | CCCCC[C@@H](/C=C/[C@@H]1C(CCCCCCC(=O)O[Si](C)(C)C)=C(O[Si](C)(C)C)C[C@H]1O)O[Si](C)(C)C | 2848.8 | Semi standard non polar | 33892256 | Prostaglandin E1,3TMS,isomer #5 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2766.0 | Semi standard non polar | 33892256 | Prostaglandin E1,3TMS,isomer #6 | CCCCC[C@H](O)/C=C/[C@@H]1C(CCCCCCC(=O)O[Si](C)(C)C)=C(O[Si](C)(C)C)C[C@H]1O[Si](C)(C)C | 2795.7 | Semi standard non polar | 33892256 | Prostaglandin E1,3TMS,isomer #7 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C)C=C(O[Si](C)(C)C)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C | 2785.2 | Semi standard non polar | 33892256 | Prostaglandin E1,4TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1C(CCCCCCC(=O)O[Si](C)(C)C)=C(O[Si](C)(C)C)C[C@H]1O[Si](C)(C)C)O[Si](C)(C)C | 2819.7 | Semi standard non polar | 33892256 | Prostaglandin E1,4TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1C(CCCCCCC(=O)O[Si](C)(C)C)=C(O[Si](C)(C)C)C[C@H]1O[Si](C)(C)C)O[Si](C)(C)C | 2893.6 | Standard non polar | 33892256 | Prostaglandin E1,4TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1C(CCCCCCC(=O)O[Si](C)(C)C)=C(O[Si](C)(C)C)C[C@H]1O[Si](C)(C)C)O[Si](C)(C)C | 2916.2 | Standard polar | 33892256 | Prostaglandin E1,4TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C=C(O[Si](C)(C)C)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2815.5 | Semi standard non polar | 33892256 | Prostaglandin E1,4TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C=C(O[Si](C)(C)C)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2731.3 | Standard non polar | 33892256 | Prostaglandin E1,4TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C=C(O[Si](C)(C)C)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 3001.4 | Standard polar | 33892256 | Prostaglandin E1,1TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3076.9 | Semi standard non polar | 33892256 | Prostaglandin E1,1TBDMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)CC(=O)[C@@H]1CCCCCCC(=O)O | 2957.6 | Semi standard non polar | 33892256 | Prostaglandin E1,1TBDMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C | 3049.9 | Semi standard non polar | 33892256 | Prostaglandin E1,1TBDMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@@H]1C(CCCCCCC(=O)O)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O | 3067.4 | Semi standard non polar | 33892256 | Prostaglandin E1,1TBDMS,isomer #5 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCC(=O)O | 2964.6 | Semi standard non polar | 33892256 | Prostaglandin E1,2TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)CC(=O)[C@@H]1CCCCCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3212.0 | Semi standard non polar | 33892256 | Prostaglandin E1,2TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3328.6 | Semi standard non polar | 33892256 | Prostaglandin E1,2TBDMS,isomer #3 | CCCCC[C@@H](/C=C/[C@@H]1C(CCCCCCC(=O)O)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O)O[Si](C)(C)C(C)(C)C | 3317.9 | Semi standard non polar | 33892256 | Prostaglandin E1,2TBDMS,isomer #4 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3216.0 | Semi standard non polar | 33892256 | Prostaglandin E1,2TBDMS,isomer #5 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)CC(=O)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C | 3192.3 | Semi standard non polar | 33892256 | Prostaglandin E1,2TBDMS,isomer #6 | CCCCC[C@H](O)/C=C/[C@@H]1C(CCCCCCC(=O)O)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O[Si](C)(C)C(C)(C)C | 3251.4 | Semi standard non polar | 33892256 | Prostaglandin E1,2TBDMS,isomer #7 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCC(=O)O | 3216.8 | Semi standard non polar | 33892256 | Prostaglandin E1,2TBDMS,isomer #8 | CCCCC[C@H](O)/C=C/[C@@H]1C(CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O | 3288.2 | Semi standard non polar | 33892256 | Prostaglandin E1,2TBDMS,isomer #9 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C | 3216.9 | Semi standard non polar | 33892256 | Prostaglandin E1,3TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)CC(=O)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3470.1 | Semi standard non polar | 33892256 | Prostaglandin E1,3TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@@H]1C(CCCCCCC(=O)O)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3487.4 | Semi standard non polar | 33892256 | Prostaglandin E1,3TBDMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3477.4 | Semi standard non polar | 33892256 | Prostaglandin E1,3TBDMS,isomer #4 | CCCCC[C@@H](/C=C/[C@@H]1C(CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O)O[Si](C)(C)C(C)(C)C | 3559.5 | Semi standard non polar | 33892256 | Prostaglandin E1,3TBDMS,isomer #5 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C=C(O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3486.2 | Semi standard non polar | 33892256 | Prostaglandin E1,3TBDMS,isomer #6 | CCCCC[C@H](O)/C=C/[C@@H]1C(CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O[Si](C)(C)C(C)(C)C | 3464.7 | Semi standard non polar | 33892256 | Prostaglandin E1,3TBDMS,isomer #7 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C | 3469.8 | Semi standard non polar | 33892256 | Prostaglandin E1,4TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1C(CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3683.6 | Semi standard non polar | 33892256 | Prostaglandin E1,4TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1C(CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3480.9 | Standard non polar | 33892256 | Prostaglandin E1,4TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@@H]1C(CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)C[C@H]1O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3243.3 | Standard polar | 33892256 | Prostaglandin E1,4TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3692.6 | Semi standard non polar | 33892256 | Prostaglandin E1,4TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3213.4 | Standard non polar | 33892256 | Prostaglandin E1,4TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3276.5 | Standard polar | 33892256 |
|
---|
General References | - Borsick M, Rajkhowa T, Taub M: Evidence for post-transcriptional regulation of Na,K-ATPase by prostaglandin E1. Biochem Biophys Res Commun. 2006 Jun 30;345(2):739-45. Epub 2006 May 5. [PubMed:16701566 ]
- Weiss T, Fischer D, Hausmann D, Weiss C: Endothelial function in patients with peripheral vascular disease: influence of prostaglandin E1. Prostaglandins Leukot Essent Fatty Acids. 2002 Nov;67(5):277-81. [PubMed:12445486 ]
- Thum J, Caspary L, Creutzig A, Alexander K: Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease. Vasa. 1998 May;27(2):100-5. [PubMed:9612114 ]
- Foldvari M, Oguejiofor CJ: Metabolism studies on transdermal prostaglandin E1 in human foreskin in vitro. Eur J Drug Metab Pharmacokinet. 1997 Apr-Jun;22(2):111-20. [PubMed:9248778 ]
- Kornberg A, Schotte U, Kupper B, Hommann M, Scheele J: Impact of selective prostaglandin E1 treatment on graft perfusion and function after liver transplantation. Hepatogastroenterology. 2004 Mar-Apr;51(56):526-31. [PubMed:15086195 ]
- Sato Y, Suzuki N, Adachi H, Hisasue S, Horita H, Tsukamoto T: Evaluation of the alleviative action of neurotropin for penile pain associated with intracavernous injection of prostaglandin E1 assessed using the visual analogue scale. Int J Impot Res. 1998 Mar;10(1):1-3. [PubMed:9542683 ]
- Kikura M, Kazama T, Ikeda T, Sato S: Disaggregatory effects of prostaglandin E1, amrinone and milrinone on platelet aggregation in human whole blood. Platelets. 2000 Dec;11(8):446-58. [PubMed:11177444 ]
- Rady-Pentek P, Mueller R, Tang BK, Kalow W: Interindividual variation in the enzymatic 15-keto-reduction of 13,14-dihydro-15-keto-prostaglandin E1 in human liver and in human erythrocytes. Eur J Clin Pharmacol. 1997;52(2):147-53. [PubMed:9174685 ]
- Kunimoto F, Arai K, Isa Y, Koyano T, Kadoi Y, Saito S, Goto F: A comparative study of the vasodilator effects of prostaglandin E1 in patients with pulmonary hypertension after mitral valve replacement and with adult respiratory distress syndrome. Anesth Analg. 1997 Sep;85(3):507-13. [PubMed:9296401 ]
- Sinzinger H, Kritz H, Virgolini I, Schmid P, Rogatti W: Prostaglandin E1 increases binding of 123I-low-density lipoprotein to the human liver in vivo. Eur J Clin Pharmacol. 1996;49(6):515-20. [PubMed:8706779 ]
- Fabbri A, Magalotti D, Marchesini G, Brizi M, Bianchi G, Zoli M: Effects of systemic prostaglandin E1 on splanchnic and peripheral haemodynamics in control subjects and in patients with cirrhosis. Prostaglandins Other Lipid Mediat. 1998 Mar;55(4):209-18. [PubMed:9644112 ]
- Fabbri A, Bianchi G, Brizi M, Bugianesi E, Magalotti D, Zoli M, Marchesini G: Effects of systemic prostaglandin E1 on hepatic amino acid-nitrogen metabolism in patients with cirrhosis. Hepatology. 1998 Mar;27(3):815-21. [PubMed:9500712 ]
- Hawker RJ, Turner VS, Mitchell SG: Use of prostaglandin E1 during preparation of platelet concentrates. Transfus Med. 1996 Sep;6(3):249-54. [PubMed:8885155 ]
- Foldvari M, Oguejiofor CJ, Wilson TW, Afridi SK, Kudel TA: Transcutaneous delivery of prostaglandin E1: in vitro and laser doppler flowmetry study. J Pharm Sci. 1998 Jun;87(6):721-5. [PubMed:9607949 ]
- Liu XL, Fan DM: Protective effects of prostaglandin E1 on hepatocytes. World J Gastroenterol. 2000 Jun;6(3):326-329. [PubMed:11819590 ]
- Masoodi M, Nicolaou A: Lipidomic analysis of twenty-seven prostanoids and isoprostanes by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006;20(20):3023-9. [PubMed:16986207 ]
|
---|